ArticleJournal of molecular neuroscience : MN2025
Multi-tissue Methylation Analysis of Alzheimer's Disease: Insights into Pathways, Modules, and Key Genes.
Article in Journal of molecular neuroscience : MN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- HMC3 revealed: how much do these "Microglia" really tell us?Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
DNA methylation plays a crucial role in the onset and progression of Alzheimer's disease (AD). Genome-wide methylation analysis of multi-tissue data can provide insights into the pathology and diagnostic biomarkers of AD. Computational tools were employed to identify pathways associated with AD and to develop a poly-methylation score (PMS). Key genes within the identified pathways were determined through module analysis and protein-protein interaction networks followed by validation in β-amyloid 42-induced cellular models. Linear mixed-effects model was used to investigate the longitudinal relationship between PMS and changes in AD phenotypes. AD-related pathways exhibited tissue specificity. The key genes in blood, frontal cortex, neurons, and glial cells were THBS1, TGFB1, HIF1A, and KLF4, respectively. Furthermore, the expression alterations of these genes were validated in three cellular models (SH-SY5Y, HMC3, and THP-1). Notably, higher PMS was significantly correlated with accelerated declines in cerebral metabolic rate and cognitive function. Using machine learning to analyze methylation data and identify key genes in AD patients enhanced our understanding of AD pathogenesis. Further research is needed to validate the potential of these key genes as intervention targets for AD.
Indexed as
Identifiers
40670811What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.